Chemotherapy Counteracts Metastatic Dissemination Induced by
... after cediranib (a pan-VEGF-RTKI; refs. 23, 24). A retrospective analysis of five placebo-controlled phase III clinical trials in patients with breast, colorectal, renal, and pancreatic cancer did not support worse clinical outcome or altered disease progression after cessation of bevacizumab (25). ...
... after cediranib (a pan-VEGF-RTKI; refs. 23, 24). A retrospective analysis of five placebo-controlled phase III clinical trials in patients with breast, colorectal, renal, and pancreatic cancer did not support worse clinical outcome or altered disease progression after cessation of bevacizumab (25). ...
Spontaneous exudative retinal detachment in a patient with sturge
... detachments with intravitreal injection of human monoclonal antibodies against vascular endothelial growth factor (anti-VEGF) both as primary and secondary treatments [7,9,17]. This therapy is used to inhibit the formation of aberrant blood vessels and to decrease vascular permeability. The treatmen ...
... detachments with intravitreal injection of human monoclonal antibodies against vascular endothelial growth factor (anti-VEGF) both as primary and secondary treatments [7,9,17]. This therapy is used to inhibit the formation of aberrant blood vessels and to decrease vascular permeability. The treatmen ...
Analysis of acquired resistance to metronomic oral
... metronomic cyclophosphamide, targeting of tumor cell associated expression of hypoxia inducible factor-1α (HIF-1α), e.g. by low dose metronomic-like topotecan [3] or adriamycin [4] and direct tumor cell targeting, including, possibly, the putative cancer stem cell subpopulation [5, 6]. With respect ...
... metronomic cyclophosphamide, targeting of tumor cell associated expression of hypoxia inducible factor-1α (HIF-1α), e.g. by low dose metronomic-like topotecan [3] or adriamycin [4] and direct tumor cell targeting, including, possibly, the putative cancer stem cell subpopulation [5, 6]. With respect ...
The Acute Red Eye and Ocular Trauma
... • A 60yo woman initially presents to her optometrist complaining of gradual worsening of her peripheral vision. The optometrist performs this test and refers her to you, her GP, for a referral to an ...
... • A 60yo woman initially presents to her optometrist complaining of gradual worsening of her peripheral vision. The optometrist performs this test and refers her to you, her GP, for a referral to an ...
New technologies and drugs in the management of diabetic
... for more than 30 years. Sight-threatening diabetic retinopathy consists of two distinct clinical entities: proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DMO or maculopathy) which may coexist, both of which can be detected by clinical or photographic screening before vision is ...
... for more than 30 years. Sight-threatening diabetic retinopathy consists of two distinct clinical entities: proliferative diabetic retinopathy (PDR) and diabetic macular oedema (DMO or maculopathy) which may coexist, both of which can be detected by clinical or photographic screening before vision is ...
12 January 2007 - Scottish Medicines Consortium
... NSCLC with locally advanced or metastatic disease (stage III or IV) not amenable to curative therapy. Patients had to have received prior chemotherapy, have adequate organ function, an Eastern Cooperative Oncology Group performance status (PS) of 0 to 2 and an estimated life expectancy of at least 8 ...
... NSCLC with locally advanced or metastatic disease (stage III or IV) not amenable to curative therapy. Patients had to have received prior chemotherapy, have adequate organ function, an Eastern Cooperative Oncology Group performance status (PS) of 0 to 2 and an estimated life expectancy of at least 8 ...
effective non-toxic treatments for cancer are available
... to have their cancer metastasize to other sites. Other studies have supported this view. He also stated that the radioactivity intended to kill cancer cells can, instead, trigger mutations that create new cancer cells of other types.13 According to several clinical trials and a study published in “T ...
... to have their cancer metastasize to other sites. Other studies have supported this view. He also stated that the radioactivity intended to kill cancer cells can, instead, trigger mutations that create new cancer cells of other types.13 According to several clinical trials and a study published in “T ...
Role of Endogenous Vascular Endothelial Growth Factor in
... secreted from mesenchymal, stromal, and epithelial sources to act on endothelial cells. The angiogenic effects of VEGF are primarily mediated by VEGF receptor-2 (VEGFR-2).2 In 1971, Folkman proposed angiogenesis inhibition as an alternative strategy for the treatment of malignancies.3 Meanwhile, sev ...
... secreted from mesenchymal, stromal, and epithelial sources to act on endothelial cells. The angiogenic effects of VEGF are primarily mediated by VEGF receptor-2 (VEGFR-2).2 In 1971, Folkman proposed angiogenesis inhibition as an alternative strategy for the treatment of malignancies.3 Meanwhile, sev ...
13. Major R&D Pipeline In-House R&D Pipeline List New Approval
... Development Code: APD356 Generic Name: lorcaserin Product Name: BELVIQ Indications / Drug class: Anti-obesity agent / serotonin 2C receptor antagonist ...
... Development Code: APD356 Generic Name: lorcaserin Product Name: BELVIQ Indications / Drug class: Anti-obesity agent / serotonin 2C receptor antagonist ...
Retinoscopic Findings in Common Systemic Diseases
... Goal: lower levels of VEGF which is thought to promote and propagate neovascularization ...
... Goal: lower levels of VEGF which is thought to promote and propagate neovascularization ...
Retinoscopic Findings in Common Systemic Diseases
... Goal: lower levels of VEGF which is thought to promote and propagate neovascularization ...
... Goal: lower levels of VEGF which is thought to promote and propagate neovascularization ...
Retinal vein occlusion in a patient on oral contraceptive
... factors for BRVO in young patients(3,4). Oral contraceptive pills (OCP) treatment is the most common birth control method. Although well tolerated and with good safety profile, there are a couple of ocular side effects described (retinal vitreous haemorrhage, retinal vascular thrombosis or serous ch ...
... factors for BRVO in young patients(3,4). Oral contraceptive pills (OCP) treatment is the most common birth control method. Although well tolerated and with good safety profile, there are a couple of ocular side effects described (retinal vitreous haemorrhage, retinal vascular thrombosis or serous ch ...
Aflibercept for the treatment of wet age
... London New Drugs Group APC/DTC Briefing Document Aflibercept (Eylea®) for wet age-related macular degeneration March 2013 Summary Aflibercept (Eylea®) is a recombinant fusion protein which binds to and inhibits activation of vascular endothelial growth factor (VEGF-A) and Placental Growth Factor (PI ...
... London New Drugs Group APC/DTC Briefing Document Aflibercept (Eylea®) for wet age-related macular degeneration March 2013 Summary Aflibercept (Eylea®) is a recombinant fusion protein which binds to and inhibits activation of vascular endothelial growth factor (VEGF-A) and Placental Growth Factor (PI ...
Abiraterone Acetate in Combination with Prednisone for the
... 17 a-hydroxylase/C17,20-lyase (CYP17) inhibitor that acts on extragonadal testosterone production. The inhibition of CYP17 in the adrenal gland can lead to increased levels of steroids with mineralocorticoid effects, which may result in mineralocorticoid-related side effects, including hypokalemia, ...
... 17 a-hydroxylase/C17,20-lyase (CYP17) inhibitor that acts on extragonadal testosterone production. The inhibition of CYP17 in the adrenal gland can lead to increased levels of steroids with mineralocorticoid effects, which may result in mineralocorticoid-related side effects, including hypokalemia, ...
The Case for Personalized Medicine
... The life sciences community strives to improve the safety and efficacy of its products, but much more work remains. Progress in developing and adopting diagnostics to identify which medicines work best for which patients, thus reducing adverse events, has been slow. In fact, between 2000 and 2011, t ...
... The life sciences community strives to improve the safety and efficacy of its products, but much more work remains. Progress in developing and adopting diagnostics to identify which medicines work best for which patients, thus reducing adverse events, has been slow. In fact, between 2000 and 2011, t ...
PDF - The Asia-Pacific Journal of Ophthalmology
... patients improvements in vision previously unachievable. A number of anti-VEGF agents are available to treat nAMD, with aflibercept, ranibizumab, and bevacizumab being most commonly used. Aflibercept and ranibizumab are licensed for use in nAMD, but bevacizumab, originally developed for use in an on ...
... patients improvements in vision previously unachievable. A number of anti-VEGF agents are available to treat nAMD, with aflibercept, ranibizumab, and bevacizumab being most commonly used. Aflibercept and ranibizumab are licensed for use in nAMD, but bevacizumab, originally developed for use in an on ...
Oncobiguanides: Paracelsus’ law and nonconventional routes
... viewed as a mechanistically different type of anti-cancer drugs employed at doses notably higher than those used chronically when functioning as diabetobiguanides. The antimetabolite drug methotrexate (MTX) was originally developed as an anti-cancer agent and, as such, received U.S. Food and Drug Ad ...
... viewed as a mechanistically different type of anti-cancer drugs employed at doses notably higher than those used chronically when functioning as diabetobiguanides. The antimetabolite drug methotrexate (MTX) was originally developed as an anti-cancer agent and, as such, received U.S. Food and Drug Ad ...
Session 267 Diabetic macular edema clinical and anti
... Purpose: To assess “real world” visual acuity (VA) outcomes of anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME). Methods: Analysis was performed on a large database of aggregated, longitudinal EMR from a demographically diverse sample of U.S. retina specialists ...
... Purpose: To assess “real world” visual acuity (VA) outcomes of anti-vascular endothelial growth factor (VEGF) therapy for diabetic macular edema (DME). Methods: Analysis was performed on a large database of aggregated, longitudinal EMR from a demographically diverse sample of U.S. retina specialists ...
What is age-related macular degeneration (AMD) and who`s at risk?
... cells in the macula to break down, leading to loss of central vision. The macula is the area of the retina where the photoreceptors are most dense. Like a camera, the retina is the film of the eye that receives images from the other ocular structures. The retina then sends impulses to the brain for ...
... cells in the macula to break down, leading to loss of central vision. The macula is the area of the retina where the photoreceptors are most dense. Like a camera, the retina is the film of the eye that receives images from the other ocular structures. The retina then sends impulses to the brain for ...
What Is Experimental Medical Treatment
... "Clinical trials by qualified experts are a prerequisite for determination of safety and effectiveness. 11 Clinical trials are classified into three phases, and research usually progresses in order from Phase I to Phase 11.12 With respect to cancer studies, Phase I involves initial testing to determ ...
... "Clinical trials by qualified experts are a prerequisite for determination of safety and effectiveness. 11 Clinical trials are classified into three phases, and research usually progresses in order from Phase I to Phase 11.12 With respect to cancer studies, Phase I involves initial testing to determ ...
The Melanoma Research Foundation Applauds the Senate for
... awaiting review 12 years later. New sunscreen technologies currently awaiting approval in the U.S. have been widely available in Europe, Asia, and Central and South America, in some cases for more than 15 years. ...
... awaiting review 12 years later. New sunscreen technologies currently awaiting approval in the U.S. have been widely available in Europe, Asia, and Central and South America, in some cases for more than 15 years. ...
Winter 2011 - Retina Consultants of Southwest Florida
... panel of highly accredited experts will discuss treatments being investigated in laboratories in both Southwest Florida and Boston. Dr. Patricia D’Amore, the head of the Macular Degeneration Research Center at SERI, focuses her research on vascular growth and development, with an emphasis on blood ...
... panel of highly accredited experts will discuss treatments being investigated in laboratories in both Southwest Florida and Boston. Dr. Patricia D’Amore, the head of the Macular Degeneration Research Center at SERI, focuses her research on vascular growth and development, with an emphasis on blood ...
Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer
... downregulating these controls, producing an environment in which new blood vessel formation (neoangiogenesis) occurs, and thereby supporting tumour growth. Examples of factors that stimulate and inhibit angiogenesis are given in table 1. Angiostatin, an internal fragment of plasminogen, is a specifi ...
... downregulating these controls, producing an environment in which new blood vessel formation (neoangiogenesis) occurs, and thereby supporting tumour growth. Examples of factors that stimulate and inhibit angiogenesis are given in table 1. Angiostatin, an internal fragment of plasminogen, is a specifi ...
New benchmarks are needed: The experience with completing confirmatory trials... cancer drug indications that received accelerated approval by the Food...
... Anastrozole received AA in September 2002 for the adjuvant therapy of early stage breast cancer in postmenopausal women. AA was granted on the basis of an interim analysis of a randomized, double-blind, Phase III study of 9366 women that showed an improved recurrence-free survival of anastrozole-tr ...
... Anastrozole received AA in September 2002 for the adjuvant therapy of early stage breast cancer in postmenopausal women. AA was granted on the basis of an interim analysis of a randomized, double-blind, Phase III study of 9366 women that showed an improved recurrence-free survival of anastrozole-tr ...